0001209191-19-002955.txt : 20190108
0001209191-19-002955.hdr.sgml : 20190108
20190108211612
ACCESSION NUMBER: 0001209191-19-002955
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190104
FILED AS OF DATE: 20190108
DATE AS OF CHANGE: 20190108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davis Robert E
CENTRAL INDEX KEY: 0001291959
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36274
FILM NUMBER: 19517183
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BOULEVARD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc.
CENTRAL INDEX KEY: 0001567514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364742850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
BUSINESS PHONE: 212-923-3344
MAIL ADDRESS:
STREET 1: 430 EAST 29TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10016
FORMER COMPANY:
FORMER CONFORMED NAME: Oneida Resources Corp.
DATE OF NAME CHANGE: 20130122
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-04
0
0001567514
Intra-Cellular Therapies, Inc.
ITCI
0001291959
Davis Robert E
C/O INTRA-CELLULAR THERAPIES, INC.
430 EAST 29TH STREET
NEW YORK
NY
10016
0
1
0
0
SVP, Chief Scientific Officer
Common Stock
2019-01-04
4
S
0
6862
11.33
D
46691
D
Common Stock
2019-01-04
4
S
0
2702
11.80
D
43989
D
Stock Option (right to buy)
12.73
2019-01-08
4
A
0
75554
0.00
A
2029-01-07
Common Stock
75554
75554
D
Restricted Stock Units
2019-01-08
4
A
0
54988
0.00
A
Common Stock
54988
54988
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2018. The proceeds from these sales will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.77 to $11.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.78 to $11.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
On January 8, 2019, the reporting person was granted options to purchase 75,554 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Each restricted stock unit represents a contingent right to receive one share of common stock.
On January 8, 2019, the reporting person was granted 54,988 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
/s/ Lawrence J. Hineline, Attorney-in-fact
2019-01-08